collection
MENU ▼
Read by QxMD icon Read
search

Cardiology

shared collection
106 papers 0 to 25 followers
By T C
https://www.readbyqxmd.com/read/27541045/efficacy-and-safety-of-short-term-dual-versus-mono-antiplatelet-therapy-in-patients-with-ischemic-stroke-or-tia-a-meta-analysis-of-10-randomized-controlled-trials
#1
Yang Liu, Zhaoxia Fei, Wei Wang, Jingxue Fang, Meijuan Zou, Gang Cheng
Stroke is still a primary disease for death and disability all over the world. The optimal antiplatelet therapy for treatment of stroke is under controversy. We performed a meta-analysis to justify whether short-term (≤1 year) dual-antiplatelet therapy (DAPT) has advantages over mono-antiplatelet therapy. We systematically searched the databases of Cochrane library, Pubmed and Embase up to July 2016. Randomized controlled trials (RCTs) comparing DAPT with mono-antiplatelet therapy were included in our meta-analysis...
November 2016: Journal of Neurology
https://www.readbyqxmd.com/read/27620393/the-chips-randomized-controlled-trial-control-of-hypertension-in-pregnancy-study-is-severe-hypertension-just-an-elevated-blood-pressure
#2
Laura A Magee, Peter von Dadelszen, Joel Singer, Terry Lee, Evelyne Rey, Susan Ross, Elizabeth Asztalos, Kellie E Murphy, Jennifer Menzies, Johanna Sanchez, Amiram Gafni, Michael Helewa, Eileen Hutton, Gideon Koren, Shoo K Lee, Alexander G Logan, Wessel Ganzevoort, Ross Welch, Jim G Thornton, Jean-Marie Moutquin
: To determine whether clinical outcomes differed by occurrence of severe hypertension in the international CHIPS trial (Control of Hypertension in Pregnancy Study), adjusting for the interventions of "less tight" (target diastolic blood pressure [dBP] 100 mm Hg) versus "tight" control (target dBP 85 mm Hg). In this post-hoc analysis of CHIPS data from 987 women with nonsevere nonproteinuric preexisting or gestational hypertension, mixed effects logistic regression was used to compare the following outcomes according to occurrence of severe hypertension, adjusting for allocated group and the influence of baseline factors: CHIPS primary (perinatal loss or high-level neonatal care for >48 hours) and secondary outcomes (serious maternal complications), birth weight <10th percentile, preeclampsia, delivery at <34 or <37 weeks, platelets <100×10(9)/L, elevated liver enzymes with symptoms, maternal length of stay ≥10 days, and maternal readmission before 6 weeks postpartum...
November 2016: Hypertension
https://www.readbyqxmd.com/read/27500549/aspirin-for-primary-prevention-of-cardiovascular-disease-in-patients-with-diabetes-a-meta-analysis
#3
Lianne A Kokoska, Sheila M Wilhelm, Candice L Garwood, Helen D Berlie
AIMS: Aspirin use for primary prevention of cardiovascular disease (CVD) is controversial, especially in patients with diabetes. The objective of this meta-analysis was to evaluate aspirin's safety and efficacy for primary prevention of CVD [fatal or nonfatal myocardial infarction (MI), fatal or nonfatal stroke, angina, transient ischemic attack (TIA), peripheral artery disease (PAD) and revascularization] in patients with diabetes. METHODS: A literature search was conducted using the terms cardiovascular disease, aspirin, diabetes mellitus to identify trials of patients with diabetes who received aspirin for primary prevention of CVD...
October 2016: Diabetes Research and Clinical Practice
https://www.readbyqxmd.com/read/27695821/stroke-bleeding-and-mortality-risks-in-elderly-medicare-beneficiaries-treated-with-dabigatran-or-rivaroxaban-for-nonvalvular-atrial-fibrillation
#4
David J Graham, Marsha E Reichman, Michael Wernecke, Ya-Hui Hsueh, Rima Izem, Mary Ross Southworth, Yuqin Wei, Jiemin Liao, Margie R Goulding, Katrina Mott, Yoganand Chillarige, Thomas E MaCurdy, Chris Worrall, Jeffrey A Kelman
Importance: Dabigatran and rivaroxaban are non-vitamin K oral anticoagulants approved for stroke prevention in patients with nonvalvular atrial fibrillation (AF). There are no randomized head-to-head comparisons of these drugs for stroke, bleeding, or mortality outcomes. Objective: To compare risks of thromboembolic stroke, intracranial hemorrhage (ICH), major extracranial bleeding including major gastrointestinal bleeding, and mortality in patients with nonvalvular AF who initiated dabigatran or rivaroxaban treatment for stroke prevention...
October 3, 2016: JAMA Internal Medicine
https://www.readbyqxmd.com/read/27754841/%C3%AE-blockers-and-mortality-after-myocardial-infarction-in-patients-without-heart-failure-multicentre-prospective-cohort-study
#5
(no author information available yet)
No abstract text is available yet for this article.
October 17, 2016: BMJ: British Medical Journal
https://www.readbyqxmd.com/read/27663179/clinical-outcomes-associated-with-per-operative-discontinuation-of-aspirin-in-patients-with-coronary-artery-disease-a-systematic-review-and-meta-analysis
#6
Faraz Khan Luni, Haris Riaz, Abdur Rahman Khan, Talha Riaz, Muhammad Husnain, Irbaz Bin Riaz, Muhammad Shahzeb Khan, Mohammed Taleb, Yusuf Kanjwal, Christopher J Cooper, Sadik A Khuder
BACKGROUND: Postoperative state is characterized by increased thrombotic risk by virtue of platelet activation. Whether aspirin ameliorates this risk in patients with established coronary artery disease undergoing cardiac or noncardiac surgery is unknown. We conducted a systematic review and meta-analysis to compare the risk of major adverse cardiac events (MACE) and the risk of bleeding in patients with early (3-5 or more days before surgery) vs. late discontinuation(<3-5 days)/no discontinuation of aspirin...
September 24, 2016: Catheterization and Cardiovascular Interventions
https://www.readbyqxmd.com/read/27689317/the-effect-of-in-hospital-acquired-thrombocytopenia-on-the-outcome-of-patients-with-acute-coronary-syndromes-a-systematic-review-and-meta-analysis
#7
Evangelos K Oikonomou, Theodoros I Repanas, Christos Papanastasiou, Damianos G Kokkinidis, Michael Miligkos, Attila Feher, Dipti Gupta, Polydoros N Kampaktsis
BACKGROUND: In-hospital acquired thrombocytopenia (TP) is relatively common among patients hospitalized with acute coronary syndromes (ACS). However, its effect on short-term and long-term outcomes has yet to be reviewed systematically. METHODS: We conducted a systematic review and meta-analysis of clinical studies assessing the relationship between new-onset in-hospital TP and adverse outcomes among ACS patients. MEDLINE, Scopus and the Cochrane Library were searched for eligible studies published before March 20, 2016...
November 2016: Thrombosis Research
https://www.readbyqxmd.com/read/27496706/device-thrombosis-and-pre-clinical-blood-flow-models-for-assessing-antithrombogenic-efficacy-of-drug-device-combinations
#8
Sivaprasad Sukavaneshvar
Thrombosis associated with blood-contacting devices is a complex process involving several component interactions that have eluded precise definition. Extensive investigations of individual biological modules such as protein adsorption, coagulation cascade activation and platelet activation/adhesion/aggregation have provided an initial foundation for developing biomaterials for blood-contacting devices, but a material that is intrinsically non-thrombogenic is yet to be developed. The well-recognized association between fluid dynamics parameters such as shear stress, vortices, stagnation and thrombotic processes such as platelet aggregation and coagulation aggravate thrombosis on most device geometries that elicit these flow disturbances...
August 3, 2016: Advanced Drug Delivery Reviews
https://www.readbyqxmd.com/read/27481737/the-association-between-prior-statin-use-and-long-term-outcomes-after-critical-care-admission
#9
M Beed, P G Brindley, R Mahajan, I Juttner, J Campion-Smith, V G Wilson
BACKGROUND: Statins may have immunomodulatory effects that benefit critically ill patients. Therefore, we retrospectively examined the association between survival and the prescription of statins prior to admission to an intensive care unit (ICU), or high dependency unit (HDU), as a result of major elective surgery or as an emergency with a presumed diagnosis of sepsis. METHODS: We retrospectively studied critical care patients (ICU or HDU) from a tertiary referral UK teaching hospital...
October 2016: Journal of Critical Care
https://www.readbyqxmd.com/read/27516946/characteristics-of-coronary-arterial-lesions-in-patients-with-coronary-heart-disease-and-hypertension
#10
Jing-Xia Zhang, Hong-Zhi Dong, Bing-Wei Chen, Hong-Liang Cong, Jing Xu
OBJECTIVE: The aim of this study was to investigate the correlations between risk factors such as hypertension and the complex degrees of coronary arterial lesions (CAL). METHODS: We selected 462 patients with coronary heart disease (CHD) with confirmed the stenosis (≥50 %) in at least one major coronary artery on coronary angiography and divided them into the "CHD with hypertension" group (CHD-HT, n = 306) and the CHD group (n = 156). The characteristics of CAL and the occurrence of 2-year postoperative major adverse cardiac cerebrovascular events (MACCE) in the two groups were observed...
2016: SpringerPlus
https://www.readbyqxmd.com/read/27264793/coadministration-of-ticagrelor-and-ritonavir-toward-prospective-dose-adjustment-to-maintain-an-optimal-platelet-inhibition-using-the-pbpk-approach
#11
N Marsousi, C F Samer, P Fontana, J L Reny, S Rudaz, J A Desmeules, Y Daali
Ticagrelor is a potent antiplatelet drug metabolized by cytochrome (CYP)3A. It is contraindicated in patients with human immunodeficiency virus (HIV) because of the expected CYP3A inhibition by most protease inhibitors, such as ritonavir and an increased bleeding risk. In this study, a physiologically based pharmacokinetic (PBPK) model was created for ticagrelor and its active metabolite (AM). Based on the simulated interaction between ticagrelor 180 mg and ritonavir 100 mg, a lower dose of ticagrelor was calculated to obtain, when coadministered with ritonavir, the same pharmacokinetic (PK) and platelet inhibition as ticagrelor administered alone...
September 2016: Clinical Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/27595682/use-of-concomitant-aspirin-in-patients-with-atrial-fibrillation-findings-from-the-rocket-af-trial
#12
Rohan Shah, Anne Hellkamp, Yuliya Lokhnygina, Richard C Becker, Scott D Berkowitz, Günter Breithardt, Werner Hacke, Jonathan L Halperin, Graeme J Hankey, Keith A A Fox, Christopher C Nessel, Kenneth W Mahaffey, Jonathan P Piccini, Daniel E Singer, Manesh R Patel
BACKGROUND: We aimed to investigate the relationship between aspirin use and clinical outcomes in patients enrolled in Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF), in particular, those with known coronary artery disease (CAD). METHODS: Patients in ROCKET AF, comparing rivaroxaban and warfarin, were analyzed. Aspirin use was assessed at baseline...
September 2016: American Heart Journal
https://www.readbyqxmd.com/read/27401285/panax-quinquefolium-saponin-combined-with-dual-antiplatelet-drugs-inhibits-platelet-adhesion-to-injured-huvecs-via-pi3k-akt-and-cox-pathways
#13
Ming-Ming Wang, Mei Xue, Yu Miao, Na Kou, Yong-Gang Xu, Lin Yang, Ying Zhang, Da-Zhuo Shi
ETHNOPHARMACOLOGICAL RELEVANCE: Panax quinquefolium saponin (PQS) is the active component extracted from traditional Chinese medicine Panax quinquefolius L. and has been widely used as a supplement to dual antiplatelet drugs (DA) for treatment of coronary artery disease (CAD) for two decades; however, the efficacy of PQS combined with DA against platelet adhesion to endothelial cells (ECs), an essential step in thrombosis, remains unclear. AIM OF THE STUDY: To compare PQS combined with DA and DA alone in inhibiting platelet adhesion to injured human umbilical vein endothelial cells (HUVECs) and to explore the possible mechanisms focusing on PI3K/AKT, COX-2/6-keto-PGF1α, and COX-1/TXB2 pathways...
July 8, 2016: Journal of Ethnopharmacology
https://www.readbyqxmd.com/read/27543264/management-of-bleeding-in-patients-treated-with-direct-oral-anticoagulants
#14
REVIEW
Marcel Levi
BACKGROUND: Recently, a new generation of direct-acting oral anticoagulants (DOACs) with a greater specificity towards activated coagulation factors was introduced based on encouraging results for efficacy and safety in clinical studies. An initial limitation of these new drugs was the absence of an adequate strategy to reverse the effect if a bleeding event occurs or an urgent invasive procedure has to be carried out. MAIN TEXT: Specific reversing agents for DOACs have become available, however, and are now evaluated in clinical studies...
August 20, 2016: Critical Care: the Official Journal of the Critical Care Forum
https://www.readbyqxmd.com/read/27659071/nonvitamin-k-antagonist-oral-anticoagulant-activity-challenges-in-measurement-and-reversal
#15
Karen S Brown, Hamim Zahir, Michael A Grosso, Hans J Lanz, Michele F Mercuri, Jerrold H Levy
BACKGROUND: Four nonvitamin K antagonist oral anticoagulants (NOACs) are approved for the prevention of stroke in patients with nonvalvular atrial fibrillation and for the treatment of venous thromboembolism. These include the direct thrombin inhibitor dabigatran and the direct factor Xa inhibitors rivaroxaban, apixaban, and edoxaban. Bleeding is a complication for all anticoagulants and concerns regarding bleeding risk and the suitability of effective reversal strategies may be a barrier to their prescription...
September 23, 2016: Critical Care: the Official Journal of the Critical Care Forum
https://www.readbyqxmd.com/read/27629776/antiplatelet-versus-anticoagulation-treatment-for-patients-with-heart-failure-in-sinus-rhythm
#16
Eduard Shantsila, Gregory Yh Lip
BACKGROUND: Morbidity in patients with chronic heart failure is high, and this predisposes them to thrombotic complications, including stroke and thromboembolism, which in turn contribute to high mortality. Oral anticoagulants (e.g. warfarin) and antiplatelet agents (e.g. aspirin) are the principle oral antithrombotic agents. Many heart failure patients with sinus rhythm take aspirin because coronary artery disease is the leading cause of heart failure. Oral anticoagulants have become a standard in the management of heart failure with atrial fibrillation...
September 15, 2016: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/27614723/efficacy-profile-of-ivabradine-in-patients-with-heart-failure-plus-angina-pectoris
#17
Jeffrey S Borer, Karl Swedberg, Michel Komajda, Ian Ford, Luigi Tavazzi, Michael Böhm, Christophe Depre, Yuna Wu, Juan Maya, Fabienne Dominjon
OBJECTIVES: In the Systolic Heart Failure Treatment with the If Inhibitor Ivabradine Trial (SHIFT), slowing of the heart rate with ivabradine reduced cardiovascular death or heart failure hospitalizations among patients with systolic chronic heart failure (CHF). Subsequently, in the Study Assessing the Morbidity-Mortality Benefits of the If Inhibitor Ivabradine in Patients with Coronary Artery Disease (SIGNIFY) slowing of the heart rate in patients without CHF provided no benefit for cardiovascular death or nonfatal myocardial infarction (primary composite end point), with secondary analyses suggesting possible harm in the angina subgroup...
September 10, 2016: Cardiology
https://www.readbyqxmd.com/read/27567408/2016-esc-guidelines-for-the-management-of-atrial-fibrillation-developed-in-collaboration-with-eacts-the-task-force-for-the-management-of-atrial-fibrillation-of-the-european-society-of-cardiology-esc-developed-with-the-special-contribution-of-the-european-heart
#18
Paulus Kirchhof, Stefano Benussi, Dipak Kotecha, Anders Ahlsson, Dan Atar, Barbara Casadei, Manuel Castella, Hans-Christoph Diener, Hein Heidbuchel, Jeroen Hendriks, Gerhard Hindricks, Antonis S Manolis, Jonas Oldgren, Bogdan Alexandru Popescu, Ulrich Schotten, Bart Van Putte, Panagiotis Vardas
No abstract text is available yet for this article.
August 27, 2016: European Heart Journal
https://www.readbyqxmd.com/read/27612553/impact-of-empagliflozin-in-patients-with-diabetes-and-heart-failure
#19
David Pham, Natalia De Albuquerque Rocha, Darren K McGuire, Ian J Neeland
Heart failure (HF) is a common disease with increased risk for mortality and morbidity among patients with type 2 diabetes mellitus (T2DM). Optimal glycemic control in this patient population is challenging as many available therapies can potentially exacerbate symptoms of HF. Empagliflozin is one in a novel class of agents, the sodium glucose co-transporter 2 (SGLT2) inhibitors, that lowers blood glucose by increasing urinary glucose excretion and improves glycemic control and lowers body weight and blood pressure...
August 4, 2016: Trends in Cardiovascular Medicine
label_collection
label_collection
7521
1
2
2016-09-18 03:13:48
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"